Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases
暂无分享,去创建一个
Jeremy A Rassen | Sebastian Schneeweiss | J. Rassen | S. Schneeweiss | A. Patrick | D. Bartels | Amanda R Patrick | Dorothee B Bartels | William Murk | W. Murk
[1] D. Margolis,et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis , 2011, The British journal of dermatology.
[2] Kyungwon Oh,et al. Data Resource Profile: The Korea National Health and Nutrition Examination Survey (KNHANES) , 2014, International journal of epidemiology.
[3] R. Carnahan,et al. A systematic review of validated methods for identifying lymphoma using administrative data , 2012, Pharmacoepidemiology and drug safety.
[4] S. Kimmel,et al. Examples of Automated Databases , 2013 .
[5] T. To,et al. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in ontario, Canada, 1996 to 2007: a population-based study. , 2010, Archives of internal medicine.
[6] S. Suissa. Immeasurable time bias in observational studies of drug effects on mortality. , 2008, American journal of epidemiology.
[7] J. Rassen,et al. Effects of expanding the look‐back period to all available data in the assessment of covariates , 2017, Pharmacoepidemiology and drug safety.
[8] A. Armstrong,et al. Psoriasis prevalence among adults in the United States. , 2014, Journal of the American Academy of Dermatology.
[9] P. Lakatos,et al. The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.
[10] R. Tamblyn,et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.
[11] Shawn N Murphy,et al. Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research , 2017, Epidemiology.
[12] P. Farrell,et al. The prevalence of cystic fibrosis in the European Union. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[13] Sebastian Schneeweiss,et al. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? , 2017, Clinical pharmacology and therapeutics.
[14] E. Loftus,et al. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] J. Farley,et al. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. , 2015, Journal of comparative effectiveness research.
[16] Robin M. Murray,et al. Incidence of Schizophrenia and Other Psychoses in England, 1950–2009: A Systematic Review and Meta-Analyses , 2012, PloS one.
[17] Ben Birkman,et al. The Cystic Fibrosis Foundation , 2017 .
[18] M. Graffar. [Modern epidemiology]. , 1971, Bruxelles medical.
[19] E. Susser,et al. Incidence and cumulative risk of treated schizophrenia in the prenatal determinants of schizophrenia study. , 2000, Schizophrenia bulletin.
[20] Aziz Sheikh,et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis , 2015, Journal of global health.
[21] P. J. Kelly,et al. Inflammatory bowel disease: epidemiology and management in an English general practice population , 2000, Alimentary pharmacology & therapeutics.
[22] Ken Kleinman,et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[24] R. Carnahan,et al. Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research , 2012, Pharmacoepidemiology and drug safety.
[25] S. Schneeweiss,et al. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs , 2016, Clinical pharmacology and therapeutics.
[26] L. Lix,et al. Influence of Using Different Databases and ‘Look Back’ Intervals to Define Comorbidity Profiles for Patients with Newly Diagnosed Hypertension: Implications for Health Services Researchers , 2016, PloS one.
[27] J. Avorn,et al. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments , 2012, BMC Medical Research Methodology.
[28] K. Rascati,et al. Estimating the direct and indirect costs for community‐dwelling patients with schizophrenia , 2013 .
[29] E. Faerstein,et al. A DICTIONARY OF EPIDEMIOLOGY , 2016 .
[30] S. Gabriel,et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. , 2009, Journal of the American Academy of Dermatology.
[31] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[32] K. Fox,et al. Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study , 2013, BMC Dermatology.